Biotechnology Assets SA
MAD:BST
Biotechnology Assets SA
MAD:BST
Price:
0.206
EUR
-1.9%
Market Cap:
€15m
Relative Value
The Relative Value of one
BST
stock under the Base Case scenario is
0.255
EUR.
Compared to the current market price of 0.206 EUR,
Biotechnology Assets SA
is
Undervalued by 19%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
BST
Relative Value
Base Case
0.255
EUR
Undervaluation 19%
Multiples Across Competitors
BST Competitors Multiples
Biotechnology Assets SA Competitors
Biotechnology Assets SA Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| ES |
|
Biotechnology Assets SA
MAD:BST
|
14m EUR | 5.4 | -6.7 | 12.1 | -12.1 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 690 872.8 | -160 127.7 | -194 446.1 | -192 227.3 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
398.4B USD | 6.5 | 95.2 | 15.6 | 21.7 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
198.2B USD | 5.4 | 25.7 | 14.8 | 14.8 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
180.2B USD | 6.1 | 21.2 | 13.2 | 16.3 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
121.4B USD | 10.1 | 30.7 | 23.2 | 24.2 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 091 | -533.6 | -581 | -565.5 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
78.9B USD | 5.5 | 17.5 | 13 | 14.8 | |
| AU |
|
CSL Ltd
ASX:CSL
|
68B AUD | 3.1 | 34.5 | 11.4 | 14.3 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.1 | -61.8 | -66.6 | -60.1 | |
| NL |
|
argenx SE
XBRU:ARGX
|
37.7B EUR | 10.8 | 34.7 | 37.6 | 38.4 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
